Alternating venetoclax/azacytidine and FLT3 inhibitor treatment for NPM1- and FLT3-mutated acute myeloid leukemia

被引：2
|
作者：
Oya, Shuki [1 ]
Ozawa, Hidetoshi [1 ]
Maehiro, Yoshimi [1 ]
Nakamura, Takayuki [1 ]
Takaki, Yusuke [1 ]
Fukuyama, Toshinobu [1 ]
Yamasaki, Yoshitaka [1 ]
Yamaguchi, Maki [1 ]
Aoyama, Kazutoshi [1 ]
Mouri, Fumihiko [1 ]
Nagafuji, Koji [1 ]
机构：
[1] Kurume Univ, Dept Med, Div Hematol & Oncol, Sch Med, 67 Asahi Machi, Kurume 8300011, Japan
来源：
LEUKEMIA RESEARCH | 2023年 / 130卷
关键词：
Acute myeloid leukemia; Venetoclax; Azacytidine; FLT3; inhibitor; Nucleophosmin; Measurable residual disease; RESIDUAL DISEASE; NUCLEOPHOSMIN; CHEMOTHERAPY; VENETOCLAX;
D O I：
10.1016/j.leukres.2023.107313
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia
    Fathi, Amir T.
    Chen, Yi-Bin
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2017, 98 (04) : 330 - 336
  • [2] "FLipping" the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors
    Knight, Tristan E.
    Edwards, Holly
    Meshinchi, Soheil
    Taub, Jeffrey W.
    Ge, Yubin
    CANCERS, 2022, 14 (14)
  • [3] Treatment With FLT3 Inhibitor in Patients With FLT3-Mutated Acute Myeloid Leukemia Is Associated With Development of Secondary FLT3-Tyrosine Kinase Domain Mutations
    Alvarado, Yesid
    Kantarjian, Hagop M.
    Luthra, Rajyalakshmi
    Ravandi, Farhad
    Borthakur, Gautam
    Garcia-Manero, Guillermo
    Konopleva, Marina
    Estrov, Zeev
    Andreeff, Michael
    Cortes, Jorge E.
    CANCER, 2014, 120 (14) : 2142 - 2149
  • [4] Midostaurin in FLT3-Mutated Acute Myeloid Leukemia
    Eskazan, A. Emre
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (19) : 1901 - 1901
  • [5] Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
    Daver, Naval
    Perl, Alexander E.
    Maly, Joseph
    Levis, Mark
    Ritchie, Ellen
    Litzow, Mark
    McCloskey, James
    Smith, Catherine C.
    Schiller, Gary
    Bradley, Terrence
    Tiu, Ramon, V
    Naqvi, Kiran
    Dail, Monique
    Brackman, Deanna
    Siddani, Satya
    Wang, Jing
    Chyla, Brenda
    Lee, Paul
    Altman, Jessica K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (35) : 4048 - +
  • [6] Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia
    Kugler, Eitan
    Cohen, Inbar
    Amitai, Irina
    Ram, Ron
    Frisch, Avraham
    Nachmias, Boaz
    Canaani, Jonathan
    Moshe, Yakir
    Krayem, Baher
    Aumann, Shlomzion
    Henig, Israel
    Vainstein, Vladimir
    Shargian, Liat
    Ganzel, Chezi
    Yeshurun, Moshe
    Levi, Itay
    Raanani, Pia
    Akria, Luiza
    Ofran, Yishai
    Shimony, Shai
    Wolach, Ofir
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (03) : 932 - 941
  • [7] Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy
    Ruglioni, Martina
    Crucitta, Stefania
    Luculli, Giovanna Irene
    Tancredi, Gaspare
    Del Giudice, Maria Livia
    Mechelli, Sandra
    Galimberti, Sara
    Danesi, Romano
    Del Re, Marzia
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 201
  • [8] Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia
    McMahon, Christine M.
    Perl, Alexander E.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (09) : 841 - 849
  • [9] Incorporating FLT3 inhibitors in the frontline treatment of FLT3 mutant acute myeloid leukemia
    Wang, Eunice S.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2019, 32 (02) : 154 - 162
  • [10] Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia
    Solana-Altabella, Antonio
    Ballesta-Lopez, Octavio
    Megias-Vericat, Juan Eduardo
    Martinez-Cuadron, David
    Montesinos, Pau
    EXPERT OPINION ON EMERGING DRUGS, 2022, 27 (01) : 1 - 18
12345